



Facsimile

To: ASX Announcements

Fax: 1300 300 021

From: Mark Compton

Date: 21 November 2002

Pages: 10 (Including cover sheet)

Re: SciGen Presentation given at Sonic Healthcare AGM

SciGen Presentation given at Sonic Healthcare AGM

Please find herewith a copy of a presentation on SciGen Limited, delivered by the Managing Director of SciGen at the Sonic Healthcare Annual General Meeting held on 13 November 2002.

This presentation is for release to the market.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Mark Compton', with a large circular flourish at the end.

Mark Compton
Chief Executive Officer & Managing Director




SciGen Limited

Spin -out and ASX Listing

November 2002


Mark Compton

Chief Executive Officer and
Managing Director



Introduction

- SciGen Limited is a bio-pharmaceutical company focussed on the Asia Pacific Region.
- The Company has a portfolio of licensed products.
- SciGen is incorporated in Singapore. SciGen will trade on the ASX by way of CUFS.
- SciGen is being spun-out of Sonic via a Scheme of Arrangement.
- Sonic will hold a 12% continuing interest in SciGen following the spin-out, subject to a 24 month escrow.
- SciTech Genetics (26% shareholder) and Sonic Directors will also be subject to a 24 month escrow on their respective interests.



Capital Structure

	Pre Spin-out	Post Spin-out
Sonic Healthcare Limited	74%	12%
SciTech Genetics Pte Ltd	26%	26%
New Shareholders	-	62%
	100%	100%

- New shareholders will hold 1 SciGen share for every Sonic share held. SciGen will have 418,965,443 shares on issue at \$0.20 per share. A notional spin-out equity value for SciGen of \$83.8m is implied.



Use of Proceeds



- The A\$30m capital injection by Sonic into SciGen will be utilised as follows:

	A\$(000)
Research and Development and Clinical Research	4,700
Regulatory Affairs	1,100
Acquisition of Fixed Assets	1,600
Licence Costs	3,700
Market Development	1,900
General Corporate Purposes	8,900
Costs of Spin-out	900
Repayment to Sonic of Loans	7,200
Total Expenditure	30,000



Geographic Representation

- SciGen has business unit representation in the following countries/regions:



Product Portfolio

- SciGen's product portfolio comprises a range of products.

Product	Application	Estimated World Market \$US
• Sci-B-Vac	3 rd generation hepatitis B vaccine	800M
• SciTropin	human growth hormone	1600M
• SciLin	human insulin	2700M
• SciFeron	Interferon 2b	1800M
• SciDaPt-Vac	Diphtheria, whooping cough and tetanus	
• SciDaPT/HB-Vac	DaPT and tetanus and hepatitis B combination	
• SciTojet 2	Needle free injection device	



Sci-B-Vac

- **What is Sci-B Vac™ ?**

Sci-B-Vac™ is a third generation recombinant hepatitis B vaccine

- **Immunisation and conditions targeted by Sci-B-Vac™**

Sci-B-Vac™ is a vaccination against hepatitis B.

Sci-B-Vac could be used together with anti-viral agents for the treatment of patients with chronic hepatitis B infection.



Sci-B-Vac


- **Important features**

- Sci-B-Vac™ new proprietary vaccine
- Elicits a high antibody response
- Response is fast (fewer than three doses)
- Highly effective in “non-responder” group
- Early data suggests role as a therapeutic vaccine



SciTropin

- **What is SciTropin™ ?**
SciTropin™, is identical to natural human growth hormone.
- **Diseases and conditions targeted by human growth hormone**
 - Turner's syndrome
 - short stature due to pituitary growth hormone deficiency
 - short stature associated with renal insufficiency
 - Cachexia in AIDS wasting
 - Growth Hormone Deficiency in adults
- **Advantage**
The advantage of SciTropin is its ability to be administered by a needle free device (SciTojet)



SciLin

- **What is SciLin™ ?**
SciLin™ is recombinant human insulin.
- **Diseases and conditions targeted by SciLin™**
Insulin is used in treating diabetes.
- **Advantage**
Potentially administerable via needle free device (SciTojet), and a price advantage to some extent.



SciFeron


- **What is SciFeron™ ?**

SciFeron™ is a highly homogenous, methionine-free recombinant human interferon.

- **Diseases and conditions are targeted by SciFeron™**

Interferon is used in treating virological, oncological and haematological diseases; such as:

- Chronic viral hepatitis B
- Chronic viral hepatitis C
- Malignant melanoma
- Hairy cell leukaemia
- AIDS related Kaposi's sarcoma
- Condylonata acuminata (venereal warts)
- Herpes zoster in cancer patients
- Herpes kerato-conjunctivitis



Sci-DaPT-Vac

- **What is Sci DaPT Vac™ ?**

Sci DaPT™ is a second generation DaPT™ vaccine licensed from Kaketsuken Institute of Japan.


- **Diseases and conditions targeted by Sci DaPT™**

The vaccine is designed to be effective against:

- Diphtheria
- Whooping cough; and
- Tetanus

- **What is Sci DaPT/HB Vac™ ?**

Sci DaPT/HB Vac™ is a non generic diphtheria, whooping cough, tetanus and hepatitis B combination (quadrivalent vaccine).



SciTojet

- SciTojet™ - Needle Free Delivery of SciTropin™ and SciLin™


When pressed, the indicator button releases a fine stream of SciTropin™ without a needle


An automatic safety switch for easy control of injection

The dosage window shows how many units of SciTropin™ have been drawn into the Needle-Free Syringe

A sterile, disposable Needle-Free Syringe is reusable for 7 days

The Needle-Free Syringe provides a clear view of the full dose.




 SciGen

Timetable for Future Registrations

- The anticipated medium term timetable for registration of SciGen's product portfolio is as follows.


Product	Country	Approval
Sci-B-Vac	Hong Kong	Q2 2003
SciTropin	New Zealand	Q4 2002
Sci-B-Vac	Philippines	Approved
SciLin	India	Q4 2002
Sci-B-Vac	Singapore	Q4 2002
Sci-B-Vac	India	Q2 2003
Insulin	Korea	Q3 2003
Sci-B-Vac	Australia	Q2 2004

 SciGen

Partners

- SciGen's major business partners are presented below.

Partner	Country
Bio-Technology General (BTG)	USA
Peptotech Inc	USA
Shreya Life Sciences	India
Akzo Nobel	The Netherlands
Bioton	Poland
Ranbaxy Laboratories Limited	India
Antares Pharma Inc	USA & Switzerland
Zuellig Pharma	Asia




Board of Directors

Paul Freiman BSc, PhMb	Chairman
Saul Mashaal PhMb, MBA	Executive Director & Vice Chairman
Dr Colin Goldschmidt MBBCh, FRCPA, FAICD	Non-Executive Director
Christopher Wilks B Comm, FAICD	Non-Executive Director
Kenneth Gross CPA, MBA	Non-Executive Director
Barrie Martin BEc, ANZIF	Non-Executive Director
Peter Campbell FCA, FTIA, MAICD	Non-Executive Director
Mark Compton BSc (Pharmacology), MBA, MAICD, AFCHSE, FAIM	Managing Director & Chief Executive Officer



Scientific Advisory Board

Professor Marian Gorecki	Israel	Ph.D
Professor Chan Soh Ha	Singapore	MBBS, Ph.D
Professor Daniel Shouval	Israel	MD
Dr Yitzhak Stabinsky	California	Ph.D
Professor David J Handelsman	Sydney	MB BS, PH.D, FRACP



SciGen Limited

Spin -out and ASX Listing

November 2002

Mark Compton

Chief Executive Officer and
Managing Director

